Methods
This study was conducted according to the PRISMA
(Preferred Reporting Items for
Systemic review and Meta-Analysis) statement. We searched for
publications on the PubMed, Embase, Cochrane Central Register of
Controlled Trials, Clinical trials, CNKI, Wanfang Data, VIP, CBM up to
August 2021. We compiled 5 studies; a main Meta-analysis forest plots
were conducted for the values of the proportion of patients whose
modified Rankin scale(MRS) score was 0-1 at day 90. A sensitivity
analysis was performed with a mean
difference (MD) of the efficacy of fingolimod plus standardized
treatment versus standardized treatment alone. Random effect karyotype
is used for Meta-analysis regardless of the I2 index. The methodological
quality of each randomized controlled trial (RCTs) was assessed
according to the Cochrane Collaboration tool to assess the risk of bias
(ROB).